DDInter458 DDInter585
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg). Doravirine is formally indicated for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment experience, further expanding the possibility and choice of therapeutic treatments available for the management of HIV-1 infection.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Ivacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Cyclosporine {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Ivacaftor
Ivacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Cyclosporine {u} (Compound) causes {v} (Side Effect) Hyperaesthesia
Hyperaesthesia {u} (Side Effect) is caused by {v} (Compound) Ivacaftor
Ivacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Cyclosporine {u} (Compound) causes {v} (Side Effect) Hyperaesthesia
Hyperaesthesia {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doravirine
Cyclosporine {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doravirine
Cyclosporine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Doravirine
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Praziquantel
Praziquantel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doravirine
Cyclosporine {u} (Compound) causes {v} (Side Effect) Infestation
Infestation {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Doravirine
Cyclosporine {u} (Compound) downregulates {v} (Gene) CSK
CSK {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Cyclosporine {u} (Compound) upregulates {v} (Gene) CCNA1
CCNA1 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound) and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Cyclosporine (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Ivacaftor (Compound) and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Cyclosporine (Compound) causes Hyperaesthesia (Side Effect) and Hyperaesthesia (Side Effect) is caused by Ivacaftor (Compound) and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Cyclosporine (Compound) causes Hyperaesthesia (Side Effect) and Hyperaesthesia (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Doravirine
Cyclosporine (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Doravirine
Cyclosporine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound) and Dabrafenib may lead to a major life threatening interaction when taken with Doravirine
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Praziquantel (Compound) and Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Doravirine
Cyclosporine (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Dabrafenib (Compound) and Dabrafenib may lead to a major life threatening interaction when taken with Doravirine
Cyclosporine (Compound) downregulates CSK (Gene) and CSK (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Cyclosporine (Compound) upregulates CCNA1 (Gene) and CCNA1 (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a minor interaction that can limit clinical effects when taken with Doravirine